Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ.
Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent and selective cytotoxicity. The recognition mechanism is not MHC restricted and not dependent on a single antigen.
Gamma delta T cells act as orchestrators of an immune response. Modulation of these cells in situ therefore provides the potential to increase immunogenicity even in tumours with low mutational load which have proven challenging with other immunotherapies.
Recognition of tumors by gamma delta T cells is not dependent on any single tumor antigen and our modulating antibodies therefore have potential in a range of disease indications, including both haematological and solid malignancies. A positive correlation between γδ T cell infiltration and prognosis/survival in patients has been published in a range of Oncology indications.